2. Search Result
Search Result
Results for "

glucose-induced

" in MedChemExpress (MCE) Product Catalog:

42

Inhibitors & Agonists

15

Peptides

12

Natural
Products

1

Isotope-Labeled Compounds

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-13755
    Sulforaphane
    Maximum Cited Publications
    69 Publications Verification

    		 HDAC Keap1-Nrf2 Apoptosis Bcl-2 Family Caspase Reactive Oxygen Species (ROS) Inflammation/Immunology Cancer
    Sulforaphane is an orally active inducer of the Keap1/Nrf2/ARE pathway. Sulforaphane promotes the transcription of tumor-suppressing proteins and effectively inhibits the activity of HDACs. Through the activation of the Keap1/Nrf2/ARE pathway and further induction of HO-1 expression, Sulforaphane protects the heart. Sulforaphane suppresses high glucose-induced pancreatic cancer through AMPK-dependent signal transmission. Sulforaphane exhibits both anticancer and anti-inflammatory properties .
    Sulforaphane
  • HY-P0055
    GLP-1(7-37)
    5+ Cited Publications

    		 GLP Receptor Metabolic Disease
    GLP-1(7-37) is an intestinal insulinotropic hormone that augments glucose induced insulin secretion.
    GLP-1(7-37)
  • HY-108611
    AACOCF3
    4 Publications Verification

    Arachidonyl trifluoromethyl ketone

    		 Phospholipase Cardiovascular Disease
    AACOCF3 (Arachidonyl trifluoromethyl ketone) is a cell-permeant trifluoromethyl ketone analog of arachidonic acid. AACOCF3 is a potent and selective slow binding inhibitor of the 85-kDa cytosolic phospholipase A2 (cPLA2). AACOCF3 blocks production of arachidonate and 12-hydroxyeicosatetraenoic acid by calcium ionophore-challenged platelets. AACOCF3 inhibits glucose-induced insulin secretion from isolated rat islets. AACOCF3 has the potential for the research of cardiovascular disease .
    AACOCF3
  • HY-N0330
    Momordin Ic
    5 Publications Verification

    		 Apoptosis Autophagy PI3K c-Myc Metabolic Disease Inflammation/Immunology Cancer
    Momordin Ic is an orally active triterpenoid saponin that can be isolated from Kochia scoparia. It is also a SUMO specific protease 1 (SENP1) inhibitor, SENP1/c-MYC signaling pathway inhibitor, and apoptosis inducer. Momordin Ic induces autophagy and apoptosis in liver cancer cells through the PI3K/Akt and MAPK signaling pathways mediated by reactive oxygen species. Momordin Ic has the ability to control glucose induced blood glucose elevation, inhibit gastric emptying, resist rheumatoid arthritis, reduce CCl4 (HY-Y0298) induced hepatotoxicity and anti-tumor activity .
    Momordin Ic
  • HY-P0054
    GLP-1(7-36), amide acetate
    Maximum Cited Publications
    9 Publications Verification

    Glucagon-like peptide-1 (GLP-1)(7-36), amide acetate; Human GLP-1 (7-36), amide acetate

    		 GCGR Metabolic Disease
    GLP-1(7-36), amide acetate is a major intestinal hormone that stimulates glucose-induced insulin secretion from β cells.
    GLP-1(7-36), amide acetate
  • HY-P1856
    Proinsulin C-peptide (human)
    1 Publications Verification

    		 Insulin Receptor PDGFR MAPKAPK2 (MK2) Cardiovascular Disease Metabolic Disease Inflammation/Immunology
    Proinsulin C-peptide (human) is a peptide consisting of 31 amino acids that links the A and B chains of proinsulin to ensure its correct folding. Proinsulin C-peptide (human) inhibits the high glucose-induced increase in PDGF-β receptor protein expression and the phosphorylation of p42/p44 MAP kinase. Proinsulin C-peptide (human) increases the deformability of erythrocytes derived from type 1 diabetes, inhibits insulin-induced neointimal thickening, and suppresses the proliferation of rat aortic smooth muscle cells cultured under high-glucose conditions .
    Proinsulin C-peptide (human)
  • HY-P0055A
    GLP-1(7-37) acetate
    5+ Cited Publications

    		 GLP Receptor Metabolic Disease
    GLP-1(7-37) acetate is an intestinal insulinotropic hormone that augments glucose induced insulin secretion .
    GLP-1(7-37) acetate
  • HY-P1782
    Calcitonin (8-32), salmon

    		Amylin Receptor Metabolic Disease
    Calcitonin (8-32), salmon is a highly selective Amylin receptor antagonist. Calcitonin (8-32), salmon reverses the Amylin-mediated inhibition of glucose-induced insulin release, but has no effect on either glucagon release or somatostatin release. Calcitonin (8-32), salmon can be used for studies related to β-cell amylin .
    Calcitonin (8-32), salmon
  • HY-13413
    Tofogliflozin hydrate
    4 Publications Verification

    CSG-452 hydrate

    		 SGLT Reactive Oxygen Species (ROS) Metabolic Disease
    Tofogliflozin hydrate (CSG-452 hydrate) is a potent and highly specific sodium/glucose cotransporter 2 (SGLT2) inhibitor with an IC50 of 2.9 nM and Ki values of 2.9 nM, 14.9 nM, and 6.4 nM for human, rat, and mouse SGLT2 . Tofogliflozin partially inhibits high glucose-induced reactive oxyen species (ROS) generation in tubular cells .
    Tofogliflozin hydrate
  • HY-B1350A
    Fusidic acid sodium salt
    2 Publications Verification

    Sodium fusidate; SQ-16360

    		 Bacterial Antibiotic Interleukin Related Infection Inflammation/Immunology
    Fusidic acid sodium salt is an orally available antibacterial agent that inhibits bacterial protein synthesis by preventing the release of translation elongation factor G (EF-G) from ribosomes. Fusidic acid sodium salt inhibits the inhibitory and activating effects of interleukins IL-1 and IL-6 on glucose-induced insulin production and exhibits antidiabetic effects in a rat model. Fusidic acid sodium salt improves the symptoms of colitis in rats and inhibits the growth of Toxoplasma gondii and Listeria monocytogenes EGD in vitro, but not in mice .
    Fusidic acid sodium salt
  • HY-134353B
    ADP-β-S trilithium

    Adenosine 5'-β-thiodiphosphate trilithium

    		 P2Y Receptor NF-κB Interleukin Related Caspase Neurological Disease Inflammation/Immunology Cancer
    ADP-β-S (Adenosine 5'-(β-thiodiphosphate)) trilithium is a non-hydrolyzable ADP analog and a P2Y12 receptor agonist. ADP-β-S trilithium activates the P2Y12 receptor in microglia, thereby triggering downstream inflammatory signaling pathways. ADP-β-S trilithium activates P2Y purinergic receptors in rat pancreatic β cells and enhances glucose-induced insulin secretion. ADP-β-S trilithium can be used in the research of diseases such as inflammation and diabetes .
    ADP-β-S trilithium
  • HY-P0054B
    GLP-1(7-36), amide TFA
    Maximum Cited Publications
    9 Publications Verification

    Glucagon-like peptide-1 (GLP-1)(7-36), amide TFA; Human GLP-1 (7-36), amide TFA

    		 GCGR Metabolic Disease
    GLP-1(7-36), amide TFA is a major intestinal hormone that stimulates glucose-induced insulin secretion from β cells .
    GLP-1(7-36), amide TFA
  • HY-W229874
    EN106

    		E1/E2/E3 Enzyme NF-κB Reactive Oxygen Species (ROS) SOD Cancer
    EN106 is a potent inhibitor of FEMIB. EN106 is a cysteine-reactive covalent ligand. EN106 disrupts recognition of the key reductive stress substrate of FEM1B, FNIP1. EN106 reduces oxidative stress and rescues high glucose-induced impaired angiogenesis in HUVECs .
    EN106
  • HY-126415
    Magnesium Lithospermate B
    1 Publications Verification

    		 Na+/K+ ATPase Cardiovascular Disease Neurological Disease Inflammation/Immunology
    Magnesium Lithospermate B, is a derivative of caffeic acid tetramer and an inhibitor of Na+/K+ ATPase, which can be extracted from Salviae miltiorrhizae. Magnesium Lithospermate B is widely used for the research of cardiovascular diseases, and it can protect against glucose-induced intracellular oxidative damage. Magnesium Lithospermate B also suppresses neuroin?ammation and attenuates neurodegeneration .
    Magnesium Lithospermate B
  • HY-126411
    Peonidin-3-O-galactoside chloride

    		Lipase ATP Synthase Others
    Peonidin-3-O-galactoside chloride is an anthocyanin with antioxidant properties and blood-brain barrier permeability. Peonidin-3-O-galactoside chloride inhibits pancreatic lipase, with an IC50 value of 23.2 μg/mL against porcine pancreatic lipase. Peonidin-3-O-galactoside chloride mediates neuroprotection, regulates glucose metabolism, protects cells from high glucose-induced damage, promotes glucose uptake and increases ATP production. Peonidin-3-O-galactoside (chloride) can be used in the research of obesity and neurodegenerative diseases .
    Peonidin-3-O-galactoside chloride
  • HY-P5381
    gp91 ds-tat
    1 Publications Verification

    		 NADPH Oxidase Ferroptosis Reactive Oxygen Species (ROS) Glutathione Peroxidase TRP Channel Cardiovascular Disease Neurological Disease Inflammation/Immunology
    gp91 ds-tat, a biological active peptide, is a NADPH oxidase 2 (Nox2) inhibitor. gp91 ds-tat blocks NADPH oxidase-dependent superoxide production. gp91 ds-tat ameliorates high glucose-induced increase in total ROS, LPOs and iron levels. gp91 ds-tat inhibits homocysteine (Hcy)-induced activation of NLRP3 inflammasomes and restores Hcy-inhibited lysosomal TRPML1 channel activity. gp91 ds-tat improves cerebrovascular and cognitive function in APP/PS1 mice. gp91 ds-tat can be used for the study of Alzheimer’s disease (AD), glomerular inflammation and cardiovascular disease .
    gp91 ds-tat
  • HY-N6082
    Rhein 8-O-β-D-Glucopyranoside
    1 Publications Verification

    		 Apoptosis Bcl-2 Family Caspase TGF-beta/Smad Bacterial Infection Metabolic Disease Inflammation/Immunology
    Rhein 8-O-β-D-Glucopyranoside is an orally active glycoside found in Rhubarb. Rhein 8-O-β-D-Glucopyranoside attenuates high glucose-induced apoptosis, recovers altered lincRNA ANRIL and let-7a expression, reverses high glucose-altered Bcl-2 and cleaved caspase-3 protein expression, and inhibits TGF-β1/Smad signaling. Rhein 8-O-β-D-Glucopyranoside accelerates Sennoside A (HY-N0365) metabolism, stimulates sennoside A purgative activity. Rhein 8-O-β-D-Glucopyranoside inhibits bacterial biofilm formation, suppresses its virulence gene expression, and exerts antibacterial activity. Rhein 8-O-β-D-Glucopyranoside can be used for the research of diabetic nephropathy, constipation, and infection .
    Rhein 8-O-β-D-Glucopyranoside
  • HY-P1072
    PHM-27 (human)

    		CGRP Receptor Cardiovascular Disease Metabolic Disease
    PHM-27 (human) is a human prepro-vasoactive intestinal polypeptide (27 amino acid). PHM-27 (human) is a potent the human calcitonin receptor agonist with an EC50 of 11 nM. PHM-27 (human) efficiently enhances glucose-induced insulin secretion from beta cells by an autocrine mechanism .
    PHM-27 (human)
  • HY-129297
    CMPF

    		Endogenous Metabolite Metabolic Disease
    CMPF can be found in trace constituent of urine and blood. CMPF is a biomarker of type 2 diabetes. CMPF can act on the β cell and induces impaired mitochondrial function. CMPF decreases glucose-induced ATP accumulation, and induces oxidative stress. CMPF reverses hepatic lipid accumulation and improves insulin sensitivity in obese mice .
    CMPF
  • HY-P3863
    Pancreastatin (swine)

    		Ser/Thr Protease Inflammation/Immunology
    Pancreastatin (swine) is a 49-residue peptide which strongly inhibits glucose-induced insulin release. Pancreastatin (swine) can be isolated and characterized from porcine pancreas .
    Pancreastatin (swine)
  • HY-P3641A
    Kisspeptin 13 TFA

    		GnRH Receptor Neurological Disease Metabolic Disease
    Kisspeptin 13 TFA is the TFA salt form of Kisspeptin 13 (HY-P3641). Kisspeptin-13 TFA inhibits glucose-induced insulin secretion with an IC50 of 1.2 nM. Kisspeptin 13 TFA activates the hypothalamic-pituitary-adrenal (HPA) axis, causes hyperthermia, motor behavior and anxiety in rats. Kisspeptin 13 TFA interacts with α2-adrenergic and 5-HT2 serotonin receptors, exhibits antidepressant efficacy. Kisspeptin 13 TFA is an activator for GPR54 and GnRH receptor, which enhances memory and can be used in Alzheimer's disease research .
    Kisspeptin 13 TFA
  • HY-161501
    3-Fluoro-evodiamine glucose

    		GLUT Topoisomerase Apoptosis Cancer
    3-Fluoro-evodiamine glucose (Compound 8) is an evodiamine-glucose conjugate. 3-Fluoro-evodiamine glucose activates the expression of glucose transporter 1 (GLUT1), and inhibits topoisomerase I/II. 3-Fluoro-evodiamine glucose induces apoptosis and arrests the cell cycle at G2/M phase. 3-Fluoro-evodiamine glucose exhibits antitumor efficacy in vivo and in vitro, without significant toxicity .
    3-Fluoro-evodiamine glucose
  • HY-N9097
    Niazirin

    		Reactive Oxygen Species (ROS) SOD Glutathione Peroxidase PKC NADPH Oxidase Metabolic Disease Inflammation/Immunology
    Niazirin is an orally active antioxidant. Niazirin can be isolated from Moringa oleifera Lam. Niazirin reduces the production levels of ROS and MDA, while increasing the levels of superoxide dismutase SOD and glutathione peroxidase GPx. Niazirin also abolishes high glucose-induced PKCζ activation and inhibits Nox4 protein expression. Niazirin exhibits excellent free radical scavenging activity. Niazirin significantly inhibits high glucose-induced proliferation of vascular smooth muscle cells. Niazirin can be used in the research of diabetic atherosclerosis .
    Niazirin
  • HY-P3641
    Kisspeptin 13

    		GnRH Receptor Neurological Disease Metabolic Disease
    Kisspeptin 13 inhibits glucose-induced insulin secretion with an IC50 of 1.2 nM. Kisspeptin 13 activates the hypothalamic-pituitary-adrenal (HPA) axis, causes hyperthermia, motor behavior and anxiety in rats. Kisspeptin 13 interacts with α2-adrenergic and 5-HT2 serotonin receptors, exhibits antidepressant efficacy. Kisspeptin 13 is an activator for GPR54 and GnRH receptor, which enhances memory and can be used in Alzheimer's disease research .
    Kisspeptin 13
  • HY-P0262
    Galantide

    		Neuropeptide Y Receptor Neurological Disease Metabolic Disease Inflammation/Immunology Endocrinology
    Galantide, a non-specific galanin receptor antagonist, is a peptide consisting of fragments of galanin and substance P. Galantide recognizes two classes of galanin binding sites (KD<0.1 nM and ~6 nM) in the rat hypothalamus. Galantide dose dependently (IC50=1.0 nM) antagonizes the galanin-mediated inhibition of the glucose-induced insulin secretion from mouse pancreatic islets. Galantide appears to bind to a single population of SP receptors (KD~40 nM) .
    Galantide
  • HY-P2534
    C-Peptide 2, rat

    		Insulin Receptor Metabolic Disease
    C-Peptide 2, rat, 31-amino-acid peptide, is a component of proinsulin. C-Peptide 2, rat can inhibit glucose-induced insulin secretion .
    C-Peptide 2, rat
  • HY-P1401
    Protein Kinase C (19-36)

    		PKC Metabolic Disease
    Protein Kinase C (19-36) is a pseudosubstrate peptide inhibitor of protein kinase C (PKC), with an IC50 of 0.18 μM. Protein Kinase C (19-36) markedly attenuated vascular hyperproliferation and hypertrophy as well as glucose-induced suppression of natriuretic peptide receptor response .
    Protein Kinase C (19-36)
  • HY-N8466
    (-)-Lyoniresinol 9'-O-glucoside

    		Reactive Oxygen Species (ROS) Metabolic Disease
    (-)-Lyoniresinol 9'-O-glucoside is an inhibitor of ROS. (-)-Lyoniresinol 9'-O-glucoside reduces lipid accumulation and lipid metabolic disorders in FFAs-exposed HepG2 cells. (-)-Lyoniresinol 9'-O-glucoside inhibits high glucose-induced reactive oxygen species production .
    (-)-Lyoniresinol 9'-O-glucoside
  • HY-134353A
    ADP-β-S trisodium

    Adenosine 5'-(β-thiodiphosphate) trisodium

    		 Interleukin Related P2Y Receptor NF-κB Caspase Neurological Disease Inflammation/Immunology Cancer
    ADP-β-S (Adenosine 5'-(β-thiodiphosphate)) trilithium is a non-hydrolyzable ADP analog and a P2Y12 receptor agonist. ADP-β-S trilithium activates the P2Y12 receptor in microglia, thereby triggering downstream inflammatory signaling pathways. ADP-β-S trilithium activates P2Y purinergic receptors in rat pancreatic β cells and enhances glucose-induced insulin secretion. ADP-β-S trilithium can be used in the research of diseases such as inflammation and diabetes .
    ADP-β-S trisodium
  • HY-W701218
    Sulforaphane-d8

    		Reactive Oxygen Species (ROS) Cancer
    Sulforaphane-d8 is the deuterium labeled Sulforaphane (HY-13755). Sulforaphane is an orally active inducer of the Keap1/Nrf2/ARE pathway. Sulforaphane promotes the transcription of tumor-suppressing proteins and effectively inhibits the activity of HDACs. Through the activation of the Keap1/Nrf2/ARE pathway and further induction of HO-1 expression, Sulforaphane protects the heart. Sulforaphane suppresses high glucose-induced pancreatic cancer through AMPK-dependent signal transmission. Sulforaphane exhibits both anticancer and anti-inflammatory properties .
    Sulforaphane-d8
  • HY-164425
    ENT-03

    		Phosphatase STAT Metabolic Disease
    ENT-03 is a centrally acting mammalian aminosterol. ENT-03 upregulates cFos activation, inhibits PTP1b and induces phosphorylation of STAT3. ENT-03 normalizes blood glucose, induces weight loss. ENT-03 can be used in the research of type 2 diabetes and obesity .
    ENT-03
  • HY-120029
    Org-9935

    		Phosphodiesterase (PDE) Endocrinology
    Org-9935 is a selective inhibitor of PDE3 with an IC50 of 50 nM. Org-9935 inhibits maturation of oocyte in naturally selected dominant follicle in rhesus macaques. Org-9935 can augment glucose-induced insulin release in isolated rat islets with an EC50 of 20 μM .
    Org-9935
  • HY-108600
    CGP-53353

    DAPH-7

    		 PKC DNA/RNA Synthesis Cardiovascular Disease Metabolic Disease
    CGP-53353 (DAPH-7) is an potent PKC inhibitor with IC50s of 0.41 μM and 3.8 μM for PKCβII and PKCβI, respectively. CGP-53353 can inhibit glucose-induced cell proliferation and DNA synthesis in AoSMC and A10 cells. CGP-53353 can be used for researching atherosclerosis of diabetic patients .
    CGP-53353
  • HY-170572
    PB01

    		Dipeptidyl Peptidase Reactive Oxygen Species (ROS) Metabolic Disease
    PB01 is a DPP-4 inhibitor with an IC50 of 15.66 nM. It effectively inhibits high glucose-induced ROS production and mitochondrial superoxide formation while significantly reducing cellular DPP-4 expression. PB01 can also significantly lower blood glucose levels in diabetic mice. Additionally, PB01 demonstrates good safety, exhibiting almost no cytotoxicity at a concentration of 100 μM. PB01 holds potential for research in the field of diabetes .
    PB01
  • HY-113513
    5-HEPE

    		Others Cancer
    5(S)-HEPE is an active metabolite of eicosapentaenoic acid. It is formed from EPA by 5-lipoxygenase (5-LO). 5(S)-HEPE is an agonist of G protein-coupled receptor 119 (GPR119). It increases cAMP accumulation in CHO-K1 cells expressing human GPR119 when used at a concentration of 10 μM. 5(S)-HEPE increases glucose-induced insulin secretion from MING6 insulinoma pancreatic islets and glucagon-like peptide 1 (GLP-1) secretion from HuTu 80 adenocarcinoma cells when used at a concentration of 10 μM. Serum levels of 5(S)-HEPE are elevated in patients with hyperlipidemia.
    5-HEPE
  • HY-N6082R
    Rhein 8-O-β-D-Glucopyranoside (Standard)

    		Reference Standards Apoptosis Bacterial Bcl-2 Family Caspase TGF-beta/Smad Infection Metabolic Disease Inflammation/Immunology
    Rhein 8-O-β-D-Glucopyranoside (Standard) is the analytical standard of Rhein 8-O-β-D-Glucopyranoside (HY-N6083). This product is intended for research and analytical applications. Rhein 8-O-β-D-Glucopyranoside is an orally active glycoside found in Rhubarb. Rhein 8-O-β-D-Glucopyranoside attenuates high glucose-induced apoptosis, recovers altered lincRNA ANRIL and let-7a expression, reverses high glucose-altered Bcl-2 and cleaved caspase-3 protein expression, and inhibits TGF-β1/Smad signaling. Rhein 8-O-β-D-Glucopyranoside accelerates Sennoside A (HY-N0365) metabolism, stimulates sennoside A purgative activity. Rhein 8-O-β-D-Glucopyranoside inhibits bacterial biofilm formation, suppresses its virulence gene expression, and exerts antibacterial activity. Rhein 8-O-β-D-Glucopyranoside can be used for the research of diabetic nephropathy, constipation, and infection .
    Rhein 8-O-β-D-Glucopyranoside (Standard)
  • HY-P5796
    FS-2

    		Calcium Channel Neurological Disease
    FS-2 is a potent and specific L-type CaV channel inhibitor. FS-2 inhibits high K + or glucose induced L-type Ca 2+ influx in RIN beta cells .
    FS-2
  • HY-N0330R
    Momordin Ic (Standard)

    		Reference Standards Apoptosis Autophagy PI3K c-Myc Metabolic Disease Inflammation/Immunology Cancer
    Momordin Ic (Standard) is the analytical standard of Momordin Ic. This product is intended for research and analytical applications. Momordin Ic is an orally active triterpenoid saponin that can be isolated from Kochia scoparia. It is also a SUMO specific protease 1 (SENP1) inhibitor, SENP1/c-MYC signaling pathway inhibitor, and apoptosis inducer. Momordin Ic induces autophagy and apoptosis in liver cancer cells through the PI3K/Akt and MAPK signaling pathways mediated by reactive oxygen species. Momordin Ic has the ability to control glucose induced blood glucose elevation, inhibit gastric emptying, resist rheumatoid arthritis, reduce CCl4 (HY-Y0298) induced hepatotoxicity and anti-tumor activity .
    Momordin Ic (Standard)
  • HY-169251
    α-Glucosidase-IN-75

    		Glycosidase Cardiovascular Disease Metabolic Disease
    α-Glucosidase-IN-75 (compound 13) is an α-glucosidase inhibitor with an IC50 of 3.81 μM. α-Glucosidase-IN-75 can be used for the study of high glucose-induced cardiovascular diseases .
    α-Glucosidase-IN-75
  • HY-181430
    PXS 25

    		TGF-beta/Smad Metabolic Disease Inflammation/Immunology
    PXS 25 is a cation-independent mannose 6-phosphate receptor (CI-M6PR) inhibitor that inhibits CI-M6PR-mediated activation of latent TGF-β1. PXS 25 inhibits conversion of high glucose-induced latent TGF-β1 to active TGF-β1 in proximal tubule cells under normoxic conditions. PXS 25 suppresses high glucose-induced fibronectin, collagen IV production, and phosphorylated Smad 2 in proximal tubule cells under normoxic conditions. PXS 25 has antifibrotic properties in skin fibroblasts. PXS 25 can be used for the research of diabetic nephropathy .
    PXS 25
  • HY-108600R
    CGP-53353 (Standard)

    DAPH-7 (Standard)

    		 Reference Standards PKC DNA/RNA Synthesis Cardiovascular Disease Metabolic Disease
    CGP-53353 (Standard) is the analytical standard of CGP-53353 (HY-108600). This product is intended for research and analytical applications. CGP-53353 (DAPH-7) is an potent PKC inhibitor with IC50s of 0.41 μM and 3.8 μM for PKCβII and PKCβI, respectively. CGP-53353 can inhibit glucose-induced cell proliferation and DNA synthesis in AoSMC and A10 cells. CGP-53353 can be used for researching atherosclerosis of diabetic patients .
    CGP-53353 (Standard)
  • HY-124487
    GK-136901

    		NADPH Oxidase TGF-β Receptor Reactive Oxygen Species (ROS) p38 MAPK Cardiovascular Disease Metabolic Disease Inflammation/Immunology
    GK-136901 is an orally active, dual Nox1/Nox4 NADPH oxidase inhibitor with a Ki of 160 nM for Nox1 and 165 nM for Nox4. GK-136901 potently blocks high glucose-induced intracellular reactive oxygen species production, p38-MAPK phosphorylation, and upregulation of TGF-β1/2 and fibronectin (fibronectin) in renal cells. GK-136901 also inhibits the proliferation of mouse pulmonary vascular cells under hypoxic conditions. GK-136901 is applicable to the research on the pathogenesis of type 2 diabetic nephropathy, high glucose-related renal lesions and pulmonary hypertension .
    GK-136901

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: